Interpace Diagnostics Group Inc (IDXG)

Add to Watchlists
Create an Alert
0.70 +0.01  +1.71% NASDAQ Apr 22, 12:22 Delayed 2m USD
View Full Chart
IDXG Price Chart
View All Events

IDXG Events

Date Type Description
08/09/2019 16:30 EDT Misc Interpace Diagnostics Group Inc Second Quarter Earnings Conference Call in 2019
08/09/2019 Earnings Interpace Diagnostics Group Inc Second Quarter Earnings in 2019 Release
03/21/2019 Misc Interpace Diagnostics Group Inc Annual Report in 2018
03/19/2019 16:30 EDT Misc Interpace Diagnostics Group Inc Fourth Quarter Earnings Conference Call in 2018
03/19/2019 Earnings Interpace Diagnostics Group Inc Fourth Quarter Earnings in 2018 Release
11/13/2018 08:30 EST Misc Interpace Diagnostics Group Inc Third Quarter Earnings Conference Call in 2018
11/13/2018 Earnings Interpace Diagnostics Group Inc Third Quarter Earnings in 2018 Release
08/09/2018 16:30 EDT Misc Interpace Diagnostics Group Inc Second Quarter Earnings Results in 2018
08/09/2018 Earnings Interpace Diagnostics Group Inc Second Quarter Earnings Results in 2018 Release
View All Performance Charts

IDXG Total Returns Comparison

Advertisement

IDXG One Page Reports

Edit

Profile

  • URL: http://www.interpacediagnostics.com
  • Investor Relations URL: http://phx.corporate-ir.net/phoenix.zhtml?c=73639&p=irol-irhome
  • HQ State/Province: New Jersey
  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Aug. 09, 2019
  • Last Earnings Release: Mar. 19, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Interpace Diagnostics Group Inc is a United States-based integrated commercial and bioinformatics company. It is engaged in developing and commercializing molecular diagnostic tests, leveraging the technology and personalized medicine for patient diagnosis and management. The company has four commercialized molecular tests, PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts, ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and, ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay, and RespriDX for assessing metastatic versus primary lung cancer tumors. The company's customers consist of physicians, hospitals, and clinics.

IDXG Comparables

Edit

IDXG Excel Add-In Codes

  • Name: =YCI("IDXG","name")
  • Description: =YCI("IDXG","description")
  • Sector: =YCI("IDXG","sector")
  • Industry: =YCI("IDXG","industry")
  • Est. Current Fiscal Year End: =YCI("IDXG","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.